What is Solarea Bio?
Founded in 2017, Solarea Bio operates at the intersection of nutritional science and advanced biotechnology. The company is dedicated to mapping the human microbiome to unlock therapeutic potential that traditional pharmaceutical approaches have historically overlooked. By identifying specific microorganisms that influence inflammatory processes, Solarea Bio is positioning itself as a leader in the next generation of health-focused biotech. Their market position is defined by a rigorous, research-intensive approach to product development, aiming to bridge the gap between dietary intake and clinical health outcomes through proprietary, science-backed interventions.
How much funding has Solarea Bio raised?
Solarea Bio has raised a total of $26.2M across 2 funding rounds:
Series A
$11.2M
Series B
$15M
Series A (2020): $11.2M with participation from BOLD Capital Partners, Gisev Family Office, S2G Ventures, and Viking Global Investors
Series B (2023): $15M led by Viking Global Investors, BOLD Capital Partners, and S2G Ventures
Key Investors in Solarea Bio
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
BOLD Capital Partners
A venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world by identifying emerging science that can disrupt large markets.
S2G Ventures
A multi-stage food and agriculture venture fund investing in entrepreneurs whose products and services meet the shifting demands for healthy and sustainable food systems.
What's next for Solarea Bio?
With this major enterprise-level funding, Solarea Bio is poised to accelerate its clinical development pipeline and scale its research operations. The strategic focus will likely shift toward validating its lead candidates in human trials and expanding its intellectual property portfolio. As the company transitions from early-stage discovery to a more mature clinical phase, the continued support from its core investor base provides the necessary runway to navigate the regulatory landscape and establish a dominant footprint in the microbiome therapeutics market. Future growth will be contingent upon the successful translation of their probiotic discovery platform into scalable, market-ready health solutions.
See full Solarea Bio company page
